laurabbook@gmail.com

Research Treatments

Targeted Therapies Patient Forum 2022

*July 2022* This virtual program was presented on July 16th and is now available on demand. It is the 8th annual live patient forum where leading thoracic oncologists from around the world as well as lung cancer patients who are active within the patient advocacy community discuss subjects relevant to…

laurabbook@gmail.comSeptember 24, 2022

Coping With Cancer

Raising Kids While Battling Lung Cancer

By Juanita Segura for Lungcancer.net In November of 2014 when I was diagnosed with lung cancer my daughter was 17 years old and a senior in high school. My two boys were 19 and 20 years old and had already graduated from high school and were in college. My second…

laurabbook@gmail.comSeptember 24, 2022

Research Treatments

Dana Farber Webcast: Second Annual “Living with EGFR-Mutant Lung Cancer: A Virtual Forum for Patients and Caregivers”

*June 2022* During this event, information about EGFR-mutant lung cancer, research advances, symptom management, as well as hearing from patients and caregivers were discussed. Watch the webcast here.

laurabbook@gmail.comSeptember 24, 2022

Research Treatments

Is There a Role for PD-L1 Inhibitors in EGFR-Mutant or ALK-Rearranged NSCLC?

*June 2022* John Heymach, MD, PhD, discusses the poor outcomes that have been observed with immunotherapy in patients with NSCLC and EGFR mutations or ALK rearrangements. An important exception to the use of PD-L1inhibitors as first-line therapy is for patients with oncogenic drivers. This is most strongly the case with…

laurabbook@gmail.comSeptember 24, 2022

Research Treatments

Duma Discusses the Unique Challenges of Women With Lung Cancer

*June 2022* In these podcasts, Narjust Duma, MD, an assistant professor of medicine at Harvard Medical School, and physician and associate director of the Cancer Equity Program at Dana-Farber Cancer Institute, discusses lung cancer in women. Lung cancer is far and away the leading cause of cancer deaths in American…

laurabbook@gmail.comSeptember 24, 2022

Research Treatments

2022 EGFR+ Lung Cancer Rapid Recap: The Evolving State of the Science in EGFR+ NSCLC

*June 2022* Presented by CEC ONCOLOGY with Dr. Helena Yu, Dr. Natasha B. Leighl, and EGFR Resisters Cofounder Jill Feldman This Rapid Recap provides a responsive, timely, and incisive overview of data presented at the 2022 Clinical Oncology Annual Meeting (ASCO), and offers expert insights into the shifting management landscape for…

laurabbook@gmail.comSeptember 23, 2022

Coping With Cancer

Fear or Survivor’s Guilt?

By Juanita Segura for Lungcancer.net In the last 7 ½ years I’ve met so many wonderful lung cancer survivors and lost many along the way. Many of them I’ve became close with and bonded regardless of how far we are from each other. We manage to keep in touch and…

laurabbook@gmail.comSeptember 23, 2022

Research Treatments

Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer

*March 2022* Lung cancer is one of the most common malignant cancers worldwide. Specific genes are known to drive cancer growth in advanced non-small-cell lung cancer (NSCLC) and targeted therapies against these genes and their proteins have significantly improved survival. However, resistance to these therapies inevitably occurs and there is…

laurabbook@gmail.comJuly 3, 2022

Research Treatments

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report

*April 2022* Introduction: Previously, we developed a database of 693 patients with NSCLC and uncommon EGFR mutations treated with afatinib. Here, we provide an update of >1000 patients, with more data on specific mutations. Methods: Patients were identified from a prospective database developed by Boehringer Ingelheim and via literature review. Mutations were…

laurabbook@gmail.comJuly 3, 2022

Research Treatments

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

*May 2022* Key Points NSCLCs harboring oncogenic EGFR mutations or ALK rearrangements can be effectively treated with EGFR and ALK TKIs respectively. The third-generation TKI osimertinib and the ALK TKI lorlatinib are currently the most advanced and effective clinically approved agents in their respective NSCLC subsets; both agents are highly…

laurabbook@gmail.comJuly 3, 2022

Targeted Therapies Patient Forum 2022

Raising Kids While Battling Lung Cancer

Dana Farber Webcast: Second Annual “Living with EGFR-Mutant Lung Cancer: A Virtual Forum for Patients and Caregivers”

Is There a Role for PD-L1 Inhibitors in EGFR-Mutant or ALK-Rearranged NSCLC?

Duma Discusses the Unique Challenges of Women With Lung Cancer

2022 EGFR+ Lung Cancer Rapid Recap: The Evolving State of the Science in EGFR+ NSCLC

Fear or Survivor’s Guilt?

Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

GIVE TODAY

Categories

STAY CONNECTED

You Might Like

BECOME A MEMBER

WHO WE ARE

PROJECTS

ALLIANCES & RESOURCES